Craig Knott

I am an epidemiologist with a long-running interest in the use of real-world data as a means of informing policy and health improvement. I currently oversea a small team of analysts, collaborating with industry, academic institutions and charities to better understand patient treatment pathways, inequalities in care, and the effectiveness of novel therapies.

Projects: 

Endometrial Cancer Audit Pilot (ECAP)

Ovarian cancer audit feasibility pilot

Ovarian cancer audit feasibility pilot

Kidney Cancer Quality Performance Indicators

Kidney Cancer Quality Performance Indicators

Cholangiocarcinoma (AMMF)

Cholangiocarcinoma (AMMF)

CORECT-R

CORECT-R

Real-world Standing Cohorts

Real-world Standing Cohorts

Craig Knott

Principal Health Data Analyst

 

Craig is an epidemiologist by training and has spent more than a decade analysing a range of retrospective population-based datasets.

He started his career at University College London, where he studied the relationship between different dynamics of alcohol consumption and the risk of non-communicable disease, before moving on to the University of Cambridge where he developed natural experimental studies designed to explore the impact of public policy on human behaviour.

Most recently he has moved into pharmacoepidemiology, working with HDI to establish a series of real-world standing cohorts alongside international partners. Here, cancer registration data are linked to myriad healthcare datasets to explore real-world clinical practice, analyse patient survival, and monitor changes in the therapeutic landscape.

Education and Awards:

University College London, 2013-16
– PhD Epidemiology and Public Health

University College London, 2010-13
– MSc Social Epidemiology

Open University, 2004-09
– BSc Social Sciences with Social Policy

Publications:

Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year retrospective cohort study

Risks of second primary cancers among 584,965 female and male breast cancer survivors in England: a 25-year ...

Cohort study to assess geographical variation in cholangiocarcinoma treatment in England

Jose S, Zalin-Miller A, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA. Cohort study to assess ...

First-line treatment (tx) patterns and overall survival (OS) of patients (pts) with advanced Merkel cell carcinoma (aMCC) in England from 2013-2022: Results of a nationwide observational cohort study

First-line treatment (tx) patterns and overall survival (OS) of patients (pts) with advanced Merkel cell carcinoma ...

First-line treatment patterns and overall survival of patients with advanced Merkel cell carcinoma in England from 2013-2022: results of a nationwide observational cohort study

Knott CS, Mahmoudpour SH, Kearney M, Boutmy E, Verpillat P. First-line treatment patterns and overall survival of ...

Treatments into Routine Clinical Practice for the Treatment of Patients with Advanced or Metastatic Cancers

Mahmoudpour SH, Knott CS, Amin A, Boutmy E, Verpillat P. Integration of Immuno-oncology (IO) Treatments into ...

Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer

Goulden S, Heffernan K, Sen Nikitas F, et al. Outcomes of dostarlimab versus chemotherapy in post-platinum ...

Regional variation in routes to diagnosis of cholangiocarcinoma in England from 2006 to 2017

Zalin-Miller A, Jose S, Knott C, Paley L, Tataru D, Morement H, Toledano MB, Khan SA. Regional variation in routes ...

Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer

Hend Hassan; Tameera Rahman; Andrew Bacon; Craig Knott; Isaac Allen; Catherine Huntley; Lucy Loong; Yvonne ...

Amivantamab Versus Alternative Real-World Anti-Cancer Therapies in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in the US and Europe

Girard N, Wolf J, Kim TM, Leighl N, Knott CS, Li T, Cabrieto J, Diels J, Sermon J, Mahadevia P, Schioppa CA, ...

Trends in incidence, treatment and survival of Merkel cell carcinoma epidemiology in England 2004-2018

Mistry K, Levell NJ, Hollestein, Wakkee M, Hijsten T, Knott CS, et al. Trends in incidence, treatment and survival ...

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations

Chouaid, C., Bosquet, L., Girard, N. et al. An Adjusted Treatment Comparison Comparing Amivantamab Versus ...

Second primary cancer risks for female and male breast cancer survivors

Isaac Allen; Tameera Rahman; Andrew Bacon; Craig Knott; Sophie Jose; Sally Vernon; Hend Hassan; Catherine ...

Amivantimab versus real-world clinical practice in Europe and the US for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations

Girard N, Wolf J, Kron A, Scheffler M, Knott CS Bosquet L et al. Amivantimab versus real-world clinical practice ...

Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England

Kearney M, Knott CS, Mahmoudpour H, Verpillat P. Factors associated with the receipt of systemic treatment (tx) ...

Evolution of the treatment landscape in patients with advanced or metastatic cancers following the approval of immuno-oncology treatments

Mahmoudpour H, Knott CS, Amin A, Boutmy E, Verpillat P. Evolution of the treatment landscape in patients with ...

Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis

Heffernan K, Sen Nikitas FS, Shukla U, Camejo HS, Knott CS. Previously treated recurrent or advanced endometrial ...

Kidney Cancer UK Quality Performance Audit of Kidney Cancer Services in England

Kidney Cancer UK Accord. Kidney Cancer UK Quality Performance Audit of Kidney Cancer Services in England. ...

Comparison of survival outcomes between dostarlimab and comparator treatments (tx) in patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC) in England

Goulden S, Heffernan K, Nikitas FS, Shukla U, Knott CS, Hunger M, Pahwa A, Schade R. Comparison of survival ...

Short-term mortality in ovarian, fallopian tube ad primary peritoneal carcinomas across England

Ovarian Cancer Audit Feasibility Pilot Steering Group. Short-term mortality in ovarian, fallopian tube ad primary ...

Demographics and survival outcomes in patients with advanced or recurrent endometrial cancer (EC) following platinum-based doublet (PBD) in the English real-world (RW) setting

Knott CS, Heffernan K, Nikitas FS, Shukla U, Starkie-Camejo H. 812P Demographics and survival outcomes in patients ...

A registry study of relapsed or refractory multiple myeloma pre-exposed to 3 or more therapies including a proteasome inhibitor, an immunomodulatory agent and cd38-targeted monoclonal antibody therapy in England

Elsada A, Zalin-Miller A, Knott CS, Caravotas L. A registry study of relapsed or refractory multiple myeloma ...

Significant variation in treatment and survival outcomes in stage 2–4 ovarian cancer in England

Sundar SS, Knott CS, Paley L, et al. Significant variation in treatment and survival outcomes in stage 2–4 ovarian ...

Utilising Public Health England Datasets to Establish a Standing Cohort of Patients with Metastatic Bladder Cancer

Davies FJ. Knott CS, Kerr C, Adedokun L, Lockhat DM. Utilising Public Health England Datasets to Establish a ...

Geographic variation in ovarian, fallopian tube and primary peritoneal cancer treatment in England

Ovarian Cancer Audit Feasibility Pilot Steering Group. Geographic variation in ovarian, fallopian tube and primary ...

Further information:

Linkedin link Linkedin profile

Share This